Physician profile
Anna Schell
NPI 1518341734
$1,591.58
in general payments reported to CMS, 2019-2025
24 companies · $900 in 2025
The $900 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $25.45 · 2024: $666 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,592.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,591.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $185.59 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $149.78 | 2024-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $140.78 | 2024-2025 | |
| Radius Health, INC. | $139.84 | 2024-2025 | Tymlos |
| Novo Nordisk INC | $132.41 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $113.57 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.47 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $78.20 | 2024-2025 | Zepbound, Mounjaro |
| Amgen INC. | $75.40 | 2024-2025 | Otezla, Repatha, Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $72.68 | 2024-2025 | |
| Esperion Therapeutics, INC. | $58.57 | 2024-2025 | Nexletol |
| Glaxosmithkline, LLC. | $50.28 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $42.90 | 2024-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $37.56 | 2024-2025 | |
| Lundbeck LLC | $28.75 | 2025 | Rexulti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.78 | 2024 | Xifaxan |
| Itamar Medical INC | $24.91 | 2025 | Watchpatone |
| Organon LLC | $21.87 | 2024 | |
| Dexcom, INC. | $21.57 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $21.19 | 2024 | Spravato |
| Medtronic, INC. | $20.55 | 2025 | Inceptiv |
| Edwards Lifesciences Corporation | $18.80 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Tris Pharma INC | $14.90 | 2024 | Dyanavel Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.